Half of the patients treated with first-line biologic DMARDs achieved sustained, event-free remission compared with 12% of ...

Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting ...

Treatment consisted of 4-6 cycles of dose-dense intensive chemotherapy incorporating hyperfractionated cyclophosphamide/ifosfamide, high-dose cytarabine and methotrexate, doxorubicin, etoposide, ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization to RINVOQ� (upadacitinib; 15 mg, once daily) for the treatment of giant cell arteritis (GCA) in ...

Liver fibrosis is the build up of scar tissue in the liver when it tries to heal itself. Symptoms may include fatigue, ...